Kanilad

Lacosamide, the active ingredient in Kanilad, is an anticonvulsant presented as an oral tablet for oral use. It treats partial‑onset seizures in patients with epilepsy.\n\nGNH India supplies Kanilad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is indicated for the treatment of focal seizure disorders within the broader epilepsy disease category.\n\n- Partial‑onset seizures: Reduces seizure frequency as adjunctive therapy in patients with epilepsy.\n- Focal epilepsy: Provides seizure control when added to existing antiepileptic regimens.\n- Refractory epilepsy: Improves seizure management in patients not adequately controlled by other drugs.

Lacosamide may cause a range of adverse reactions, which are generally categorized by frequency and severity.\n\nCommon Side Effects:\n- Dizziness\n- Headache\n- Nausea\n- Fatigue\n- Blurred vision\n\nSerious or Rare Side Effects:\n- Cardiac conduction abnormalities (e.g., PR‑interval prolongation)\n- Suicidal ideation or behavior\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Hypersensitivity reactions including anaphylaxis\n- Elevated liver enzymes

When prescribing Lacosamide, clinicians should consider several safety and handling points.\n\n- Renal impairment: Adjust dose based on renal function.\n- Hepatic impairment: Monitor liver function tests regularly.\n- Cardiac conduction disorders: Obtain baseline ECG and monitor for PR‑interval changes.\n- Pregnancy: Use only if potential benefit justifies the unknown risk to the fetus.\n- Concomitant CNS depressants: Observe for additive sedation or respiratory depression.\n- Store at ambient temperature: Keep below 25 °C, protect from moisture and light.

Lacosamide can interact with other medicines, affecting its efficacy or safety.\n\nMajor Interactions (Avoid):\n- Strong CYP3A4 inhibitors (e.g., ketoconazole): May increase Lacosamide plasma levels.\n- Class III antiarrhythmics (e.g., amiodarone): Heightened risk of cardiac conduction disturbances.\n- Other sodium‑channel blockers (e.g., carbamazepine): Potential for additive toxicity.\n\nModerate Interactions (Monitor Closely):\n- Co‑administration with other antiepileptic drugs: May require dose adjustments.\n- Alcohol or CNS depressants: Increased sedation or dizziness.\n- Hormonal contraceptives: Possible reduction in contraceptive efficacy.